Format

Send to

Choose Destination
J Cancer Res Ther. 2019;15(7):1567-1573. doi: 10.4103/jcrt.JCRT_581_19.

Preliminary clinical efficacy of iodine-125 seed implantation for the treatment of advanced malignant lung tumors.

Author information

1
Department of Interventional Therapy, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.

Abstract

Aims:

This study aims to observe the preliminary clinical efficacy of percutaneous interstitial brachytherapy using iodine-125 seeds for the treatment of advanced malignant lung tumors.

Subjects and Methods:

This retrospective study enrolled 24 patients in our hospital with advanced malignant lung tumors between June 2013 and November 2017. Computed tomography (CT)-guided iodine-125 seed implantation therapy was administered to these patients. All patients were followed up at 3, 6, and 12 months after the operation. The clinical efficacy was evaluated by CT.

Results:

Among the 24 patients, the objective response rates at 3, 6, and 12 months after the procedure were 50.0%, 50.0%, and 33.3%, respectively. Recent occurrence of adverse reactions were observed, including four cases of pneumothorax, three cases of hemoptysis, and two cases of particle displacement.

Conclusions:

CT-guided percutaneous interstitial brachytherapy with iodine-125 seeds can be used for the treatment of lung malignant tumors. Its clinical curative effect is remarkable and it results in limited trauma, reducing the incidence of adverse reactions and improving patient quality of life.

KEYWORDS:

Brachytherapy; computed tomography guided; iodine-125 seed; malignant lung tumor

PMID:
31939439
DOI:
10.4103/jcrt.JCRT_581_19
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center